These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21298971)

  • 21. Evidence-based clinical practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition).
    Kamidono S; Ohshima S; Hirao Y; Suzuki K; Arai Y; Fujimoto H; Egawa S; Akaza H; Hara I; Hinotsu S; Kakehi Y; Hasegawa T;
    Int J Urol; 2008 Jan; 15(1):1-18. PubMed ID: 18184166
    [No Abstract]   [Full Text] [Related]  

  • 22. Endocrine therapy for prostate cancer.
    Labrie F
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):845-72. PubMed ID: 1778180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What your patient needs to know about prostate cancer.
    Held-Warmkessel J
    Nursing; 2002 Dec; 32(12):36-42; quiz N232. PubMed ID: 12468938
    [No Abstract]   [Full Text] [Related]  

  • 24. What PCPs and geriatricians need to know about robotic prostatectomy and organ-confined prostate cancer.
    Carlucci JR; Nabizada-Pace F; Samadi DB
    Geriatrics; 2009 Feb; 64(2):8-14. PubMed ID: 19256581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A critical review of the concept of total androgen ablation in the treatment of prostate cancer.
    Schulze H; Isaacs JT; Coffey DS
    Prog Clin Biol Res; 1987; 243A():1-19. PubMed ID: 3309968
    [No Abstract]   [Full Text] [Related]  

  • 26. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE.
    Aaronson D; Cowan J; Carroll P; Konety B
    BJU Int; 2010 Apr; 105(7):951-5. PubMed ID: 19889066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant endocrine therapy after radical prostatectomy for stage D1 prostate carcinoma.
    Stein A; deKernion JB
    Semin Urol; 1990 Aug; 8(3):184-9. PubMed ID: 2119049
    [No Abstract]   [Full Text] [Related]  

  • 28. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
    Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
    J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H; Messing EM; Chang C
    Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 32. Postprostatectomy radiation therapy for prostate cancer.
    Abramowitz MC; Pollack A
    Semin Radiat Oncol; 2008 Jan; 18(1):15-22. PubMed ID: 18082584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What to do if prostate cancer returns.
    Johns Hopkins Med Lett Health After 50; 2001 Dec; 13(10):6-7. PubMed ID: 11727445
    [No Abstract]   [Full Text] [Related]  

  • 34. Advanced prostate cancer: what's new in hormonal manipulation?
    Brewster SF; Gillatt DA
    Br J Hosp Med; 1993 May 19-Jun 1; 49(10):710-1, 714-5. PubMed ID: 7686805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormonal ablation therapy for metastatic prostatic carcinoma: a review.
    Leewansangtong S; Soontrapa S
    J Med Assoc Thai; 1999 Feb; 82(2):192-205. PubMed ID: 10087729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors.
    Park SC; Rim JS; Choi HY; Kim CS; Hong SJ; Kim WJ; Lee SE; Song JM; Yoon JH
    Int J Urol; 2009 Aug; 16(8):670-5. PubMed ID: 19602007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hormone therapy for prostate cancer].
    Théodore C
    Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologic basis of endocrine therapy for prostatic cancer.
    McConnell JD
    Urol Clin North Am; 1991 Feb; 18(1):1-13. PubMed ID: 1899494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival.
    Sengupta S; Blute ML; Bagniewski SM; Myers RP; Bergstralh EJ; Leibovich BC; Zincke H
    J Urol; 2006 May; 175(5):1684-90; discussion 1690. PubMed ID: 16600730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.